ライフサイエンスコーパス: potassium channel blocker

1 tion of the spread, as did the ATP-activated potassium channel blocker.

2 l fluid containing 4-aminopyridine (4-AP), a potassium channel blocker.

3 could be abolished by barium, a non-specific potassium channel blocker.

4 mol/L) plus glibenclamide (10 micromol/L), a potassium channel blocker.

5 e excitability, as is expected from a simple potassium channel blocker.

6 monly used symptomatic treatment option is a potassium channel blocker [3,4-diaminopyridine (3,4-DAP)

7 y by chronic treatment with the FDA-approved potassium channel blocker 4-aminopyridine (4-AP) improve

8 l of central hyperexcitability that uses the potassium channel blocker 4-aminopyridine (4-AP) to indu

9 ves a 48-hour preconditioning step using the potassium channel blocker 4-aminopyridine (4-AP), at a l

10 affected by spike broadening produced by the potassium channel blocker 4-aminopyridine (4-AP).

11 pioid inhibition was reduced by 65% with the potassium channel blocker 4-aminopyridine (4-AP; 100 mic

12 s of mutant Shaker IR channels and using the potassium channel blocker 4-aminopyridine (4AP).

13 t hippocampal slices by superfusion with the potassium channel blocker 4-aminopyridine in Mg(2+)-free

14 The potassium channel blocker 4-aminopyridine reliably induc

15 s and the isolated guinea pig brain with the potassium channel blocker 4-aminopyridine.

16 n mouse thalamocortical slices in vitro, the potassium channel blocker 4-AP and GABAA receptor antago

17 in EPSCs induced by either serotonin or the potassium channel blockers 4-aminopyridine (4-AP) or alp

18 ctural similarity to cone snail and scorpion potassium channel blockers, a mutant molecule, Tk-hefu,

19 the crab (Cancer borealis) cardiac ganglion, potassium channel blockers and serotonin cause increased

20 ine (4AP, molecular weight 94.1146 g/mol), a potassium-channel blocker as a growth factor alternative

21 WIN 55,212-2 was also investigated using the potassium channel blockers barium and 4-aminopyridine.

22 s virtually eliminated with the nonselective potassium channel blockers barium and cesium.

23 ections to probe interactions of an exemplar potassium channel blocker, barium, with the inward recti

24 ations to IAA-94 and DIDS were unaffected by potassium channel blockers, but were prevented by elevat

25 hich resulted in differential sensitivity to potassium channel blockers (cesium and barium) and sudde

26 A selective Ca2+-activated potassium channel blocker charybdotoxin (CTX) significan

27 r, SKF525A, but not by the calcium-activated potassium channel blocker, charybdotoxin, indicating a m

28 Applying specific potassium channel blockers diminished the hyperexcitabil

29 The prophylactic use of a specific potassium-channel blocker does not reduce mortality, and

30 ed by exposure to four concentrations of the potassium channel blocker dofetilide.

31 More recently, a potassium channel-blocker for Kv1.3 has been shown to do

32 ShK toxin, a potassium channel blocker from the sea anemone Stichodac

33 The potassium channel blockers glibenclamide (10 microM), 4-

34 sensitivity to the BK-type calcium-activated potassium channel blocker iberiotoxin.

35 efficacy of adenosine triphosphate-sensitive potassium channel blockers in human septic shock.

36 mall-conductance (SK-type) calcium-activated potassium channel blockers in normally innervated cells

37 We used a recently identified potassium channel blocker, kappa-conotoxin PVIIA, to stu

38 Other studies have suggested that a potassium-channel blocker might reduce this risk with mi

39 lucidates some recent advances in the use of potassium channel-blockers of Kv1.3 and IKCa1 to amelior

40 cium-dependent (KCa) or ATP-sensitive (KATP) potassium channel blockers on pial arteriolar CO2 reacti

41 vide a mechanism for the variable effects of potassium channel blockers on transmitter release magnit

42 Potassium channel blockers or high K+ medium, but not Ca

43 sion of cesium acetate (CsAc) and the sodium/potassium channel blocker, QX314, each blocked the effec

44 h this idea, administration of voltage-gated potassium channel blockers restores conduction and resul

45 Potassium channel blockers, such as 4-aminopyridine, ind

46 g electrical stimulation and exposure to the potassium channel blocker tetraethyl ammonium chloride (

47 pathway inhibitor PD98059, the nonselective potassium channel blocker tetraethylammonium (TEA), and

48 2 receptor antagonist cimetidine or with the potassium channel blocker tetraethylammonium chloride.

49 c channels are inhibited by the nonselective potassium channel blockers tetraethylammonium and barium

50 Local delivery of a potassium-channel blocker to the ventromedial hypothalam

51 KCl and the potassium channel blocker tolbutamide also stimulated pr

52 sing tetraethylammonium (TEA), a presynaptic potassium channel blocker, we show that the apparent red

53 By comparing DTX with other potassium channel blockers, we found that the ability to

54 (Na(+))-channel blocker, and d,l-sotalol, a potassium channel blocker, were studied in littermate mi

55 e treat embryonic chick cardiac cells with a potassium channel blocker, which leads to the initiation

56 We investigated whether d-sotalol, a pure potassium-channel blocker with no clinically significant